Profiel
Claude Wischik is associated with two companies, TauRx Therapeutics Ltd.
and TauRx Pharmaceuticals Ltd., both of which he founded in 2002.
He holds the title of Chairman at TauRx Therapeutics Ltd.
and the title of Chairman & Chief Executive Officer at TauRx Pharmaceuticals Ltd.
Actieve functies van Claude Wischik
| Bedrijven | Functie | Begin |
|---|---|---|
TauRx Pharmaceuticals Ltd.
 TauRx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology TauRx Pharmaceuticals Ltd. developes drugs and diagnostics for neurodegenerative diseases. its pipeline includes LMTX, a tau aggregation inhibitor (TAI) for Alzheimer?s and Behavioural variant frontotemporal dementia diseases; anti-synuclein, a synuclein protein; early-stage compounds for use in therapies for neurodegenerative diseases; and diagnostic tests that assist clinicians in detecting and confirming the nature of a disease and monitoring the effects of therapy. The company was founded by Claude Wischik in 2002 and is headquartered in Singapore. | Algemeen Directeur | 01-01-2002 |
TauRx Therapeutics Ltd.
 TauRx Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology TauRx Therapeutics Ltd. develops treatments and diagnostics for a range of neurodegenerative diseases. It offers tau aggregation inhibitor, LMTX, a global Phase 3 clinical trials for Alzheimer’s and behavioural-variant Frontotemporal Dementia (bvFTD). LMTXT. The company was founded by Claude Wischik and K M Seng in 2002 and is headquartered in Singapore. | Oprichter | 01-01-2002 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
TauRx Therapeutics Ltd.
TauRx Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology TauRx Therapeutics Ltd. develops treatments and diagnostics for a range of neurodegenerative diseases. It offers tau aggregation inhibitor, LMTX, a global Phase 3 clinical trials for Alzheimer’s and behavioural-variant Frontotemporal Dementia (bvFTD). LMTXT. The company was founded by Claude Wischik and K M Seng in 2002 and is headquartered in Singapore. | Health Technology |
TauRx Pharmaceuticals Ltd.
TauRx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology TauRx Pharmaceuticals Ltd. developes drugs and diagnostics for neurodegenerative diseases. its pipeline includes LMTX, a tau aggregation inhibitor (TAI) for Alzheimer?s and Behavioural variant frontotemporal dementia diseases; anti-synuclein, a synuclein protein; early-stage compounds for use in therapies for neurodegenerative diseases; and diagnostic tests that assist clinicians in detecting and confirming the nature of a disease and monitoring the effects of therapy. The company was founded by Claude Wischik in 2002 and is headquartered in Singapore. | Health Technology |
